Cargando…

Pain and Fatigue in Patients With Ankylosing Spondylitis Treated With Tumor Necrosis Factor Inhibitors: Multinational Real-World Findings

BACKGROUND/OBJECTIVE: Patients with ankylosing spondylitis (AS) experience symptoms and comorbidities that impact their health-related quality of life (HRQoL) and ability to work. This real-world, global survey was conducted among AS patients receiving tumor necrosis factor inhibitors (TNFis) to eva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strand, Vibeke, Deodhar, Atul, Alten, Rieke, Sullivan, Emma, Blackburn, Stuart, Tian, Haijun, Gandhi, Kunal K., Jugl, Steffen M., Conaghan, Philip G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612885/ https://www.ncbi.nlm.nih.gov/pubmed/32826654 http://dx.doi.org/10.1097/RHU.0000000000001544

Ejemplares similares

Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study
por: Deodhar, A., et al.
Publicado: (2020)

Relationship of pain and fatigue with health-related quality of life and work in patients with psoriatic arthritis on TNFi: results of a multi-national real-world study
por: Conaghan, P G, et al.
Publicado: (2020)

Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison
por: Maksymowych, Walter P., et al.
Publicado: (2018)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
por: van der Heijde, Désirée, et al.
Publicado: (2019)

Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK
por: Emery, Paul, et al.
Publicado: (2018)

Predicting the outcome of ankylosing spondylitis therapy
por: Vastesaeger, Nathan, et al.
Publicado: (2011)

Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing Spondylitis
por: Navarro-Compán, Victoria, et al.
Publicado: (2023)

Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study
por: Deodhar, Atul, et al.
Publicado: (2023)

Geographic Variations in Diagnosis and Treatment of Ankylosing Spondylitis in the United States: A Real-World Study
por: Deodhar, Atul, et al.
Publicado: (2021)

Persistence, Discontinuation, and Switching Patterns of Newly Initiated TNF Inhibitor Therapy in Ankylosing Spondylitis Patients in the United States
por: Hunter, Theresa, et al.
Publicado: (2019)

Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks
por: Marzo-Ortega, Helena, et al.
Publicado: (2020)

Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
por: Braun, Jürgen, et al.
Publicado: (2018)

Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab
por: Wagner, Carrie, et al.
Publicado: (2011)

Ankylosing spondylitis
Publicado: (1980)

Ankylosing spondylitis
por: Edavalath, Mukesh
Publicado: (2010)

Ankylosing Spondylitis
por: Whitfield, A. G. W.
Publicado: (1976)

Ankylosing Spondylitis
por: Ebrahimiadib, Nazanin, et al.
Publicado: (2021)

Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative
por: Colombo, Giorgio L, et al.
Publicado: (2018)

Fatigue in Ankylosing Spondylitis Is Associated With Psychological Factors and Brain Gray Matter
por: Li, Ting, et al.
Publicado: (2019)

Ankylosing spondylitis diagnosis in US patients with back pain: identifying providers involved and factors associated with rheumatology referral delay
por: Deodhar, Atul, et al.
Publicado: (2016)

Predictors of Switching Anti-Tumor Necrosis Factor Therapy in Patients with Ankylosing Spondylitis
por: Lee, Jeong-Won, et al.
Publicado: (2015)

Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Ankylosing Spondylitis
por: Perpétuo, Inês P., et al.
Publicado: (2015)

Adverse Events of Anti-Tumor Necrosis Factor α Therapy in Ankylosing Spondylitis
por: Tong, Qiang, et al.
Publicado: (2015)

The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis
por: Lee, Suhwan, et al.
Publicado: (2019)

Imaging of ankylosing spondylitis
por: Østergaard, Mikkel
Publicado: (2012)

Alexithymia in ankylosing spondylitis
por: Karabıçak, Deniz, et al.
Publicado: (2021)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
por: Braun, Jürgen, et al.
Publicado: (2011)

Changes in ankylosing spondylitis incidence, prevalence and time to diagnosis over two decades
por: Crossfield, Samantha S R, et al.
Publicado: (2021)

Exploring the prevalence and factors associated with fatigue and quality of life in patients with Ankylosing Spondylitis
por: Feki, A., et al.
Publicado: (2023)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
por: Deodhar, Atul, et al.
Publicado: (2015)

A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis
por: van der Horst-Bruinsma, Irene, et al.
Publicado: (2021)

Correction: Adverse Events of Anti-Tumor Necrosis Factor α Therapy in Ankylosing Spondylitis
por: Tong, Qiang, et al.
Publicado: (2015)

Impact of Dose Tapering of Tumor Necrosis Factor Inhibitor on Radiographic Progression in Ankylosing Spondylitis
por: Park, Jun Won, et al.
Publicado: (2016)

Drug survival of tumor necrosis factor α inhibitors in patients with ankylosing spondylitis in Korea
por: Jeong, Hyemin, et al.
Publicado: (2018)

Predicting Probability of Response to Tumor Necrosis Factor Inhibitors for Individual Patients With Ankylosing Spondylitis
por: Wang, Runsheng, et al.
Publicado: (2022)

Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib
por: Strand, Vibeke, et al.
Publicado: (2020)

Comparing symptoms, treatment patterns, and quality of life of ankylosing spondylitis and non-radiographic axial spondyloarthritis patients in the USA: findings from a patient and rheumatologist Survey
por: Hunter, Theresa, et al.
Publicado: (2021)

Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis
por: Elewski, Boni E., et al.
Publicado: (2021)

Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients
por: Maksymowych, Walter P, et al.
Publicado: (2018)

Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study
por: Braun, Jürgen, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3lanlhkpdelbblqf614nejtvhc